Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Jul;17(4):441-451.
doi: 10.1007/s11523-022-00899-6. Epub 2022 Jul 16.

Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry

Camille Verry  1 , Sébastien Vincendeau  2 , Marc Massetti  3 , Martin Blachier  3 , Alexandre Vimont  3 , Marie-Laure Bazil  4 , Pauline Bernardini  4 , Ségolène Pettré  4 , Marc-Olivier Timsit  5
Affiliations
Observational Study

Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry

Camille Verry et al. Target Oncol. 2022 Jul.

Abstract

Background: Prostate cancer (PCa) is the most frequently diagnosed cancer in men in Europe. The impact of PCa natural history and therapeutic management on the outcomes of castration-resistant prostate cancer patients with metastasis (mCRPC) remains unclear.

Objective: The objective of this study was to describe retrospectively patterns of clinical progression through diagnosis sequences before the mCRPC stage and to assess how these sequences impacted patients' disease progression and overall survival at mCRPC stage.

Patients and methods: Patients with mCRPC were identified from the Prostate Cancer Registry (PCR), an observational study in a real-world setting in 16 countries between 2013 and 2016. Patients were grouped in diagnosis sequences before mCRPC and defined by date of PCa diagnosis, first metastasis, and castration resistance. Distribution of time-to-event variables were estimated using Kaplan-Meier product-limit survival curves for overall survival (OS) and progression-free survival (PFS). Non-adjusted Cox models were conducted for efficacy endpoints (OS, PFS) to estimate hazard ratios between diagnosis sequences.

Results: At the end of study, 2859 mCRPC patients were included in this analysis. Among mCRPC four diagnosis sequences were identified: 35% developed metastases (mHSPC) before becoming castration resistant (sequence 1, metachronous mHSPC), 10% developed castration resistance (nmCRPC) before metastases (sequence 2), 27% developed metastases and castration resistance within 4 months (sequence 3) and 28% of patients were de novo mHSPC (sequence 4). Median OS was 17.7 months (interquartile range (IQR): 8.8-29.9) and PFS was 6.4 months (IQR: 3.2-12.0). The univariate analyses showed no correlation between mCRPC patients' OS or PFS and the diagnosis sequence.

Conclusion: This large European study describe four different patterns of prostate cancer progression to mCRPC stage. Our results indicate that patient survival becomes comparable after progression to mCRPC, regardless of the diagnosis sequence.

Trial registration: ClinicalTrials.gov identifier NCT02236637; registered September 2014.

PubMed Disclaimer

Conflict of interest statement

Camille Verry, Sébastien Vincendeau, and Marc-Olivier Timsit received fees from Janssen-Cilag to participate in the conception, design, interpretations, and the writing of these secondary analyses presented in this manuscript. Marie-Laure Bazil, Pauline Bernardini, and Ségolène Pettré are employees of Janssen-Cilag, Issy les Moulineaux, France. Marc Massetti, Martin Blachier, and Alexandre Vimont are employees of Public Health Expertise which was contracted by Janssen-Cilag, France to perform the Prostate Cancer Registry (PCR) secondary analyses and participate in the writing of the manuscript.

Figures

Fig. 1
Fig. 1
Flowchart of included patients. mCRPC metastatic castration resistance prostate cancer, mHSPC metastatic hormone-sensitive prostate cancer, nmCRPC non-metastatic castration-resistant prostate cancer
Fig. 2
Fig. 2
Progression of patients until mCRPC in the European Cancer Prostate Registry–Median [Q1–Q3] in years. mCRPC metastatic castration-resistant prostate cancer, mHSPC metastatic hormone-sensitive prostate cancer, nmCRPC non-metastatic castration-resistant prostate cancer, PrCa prostate cancer
Fig. 3
Fig. 3
Overall survival by diagnosis sequence - Kaplan Meier curve and hazard ratio. K prostate cancer; mCRPC metastatic castration resistance prostate cancer, mHSPC metastatic hormone-sensitive prostate cancer, nmCRPC non-metastatic castration-resistant prostate cancer
Fig. 4
Fig. 4
Progression-free survival by diagnosis sequence- Kaplan Meier curve and hazard ratio. K prostate cancer; mCRPC metastatic castration-resistant prostate cancer, mHSPC metastatic hormone-sensitive prostate cancer, nmCRPC non-metastatic castration-resistant prostate cancer
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22(11):2141–2149. doi: 10.1200/JCO.2004.10.062. - DOI - PMC - PubMed
    1. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007;178(3 Pt 2):S14–S19. - PMC - PubMed
    1. Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119–1134. doi: 10.1016/j.annonc.2020.06.011. - DOI - PubMed
    1. Paller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol. 2013;11(1):14–23. - PMC - PubMed

Publication types

Associated data

LinkOut - more resources